[Skip to Navigation]
Sign In
JAMA Insights
Clinical Update
November 2, 2020

Preparing for the 2020-2021 Influenza Season

Author Affiliations
  • 1Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
  • 2Vaccine Supply and Assurance Branch, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
JAMA. 2020;324(22):2318-2319. doi:10.1001/jama.2020.21849

As health care systems across the US are experiencing or preparing for surges in individuals with coronavirus disease 2019 (COVID-19) this fall and winter, the potential for cocirculation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses poses added challenges for clinicians and public health. Recent reports suggest that influenza activity can be influenced substantially by nonpharmaceutical measures implemented to control the spread of SARS-CoV-2 (eg, use of face masks, social distancing, restrictions on public gatherings, travel restrictions) and other factors influenced by the COVID-19 pandemic (eg, reduced domestic and international travel). In early spring of 2020, sharp declines in influenza activity coincided with implementation of SARS-CoV-2 control measures in the US.1

More recently, Australia, Chile, and South Africa experienced very low influenza virus circulation during the typical Southern Hemisphere influenza season.1 Although clinic visits for influenzalike illness have declined, with fewer respiratory specimens tested in many countries, the proportion of respiratory specimens testing positive for influenza viruses has declined markedly. However, recent increases in influenza activity, notably due to influenza A(H3N2) viruses in Southeast Asia, could have implications for spread to other regions and may forecast the potential for influenza virus circulation in areas with limited SARS-CoV-2 mitigation efforts.2 Given the public health implications of seasonal influenza and uncertainty of the extent and severity of the upcoming season, preparing for the 2020-2021 influenza season should include established influenza prevention and control measures (vaccination and antiviral treatment).

Public Health Benefit of Annual Influenza Vaccination

The 2019-2020 influenza season in the US peaked in mid-February, before extensive SARS-CoV-2 transmission occurred. Revised preliminary estimates from the Centers for Disease Control and Prevention (CDC) are that approximately 38 million influenza-related illnesses, 18 million medical visits, 400 000 hospitalizations, and 22 000 deaths occurred during 2019-2020 when influenza A(H1N1)pdm09 and influenza B viruses predominated—estimates that are lower than in prior seasons in which influenza A(H3N2) viruses predominated.3 Although the effectiveness of influenza vaccines varies from season to season and among different age groups, the public health importance of annual influenza vaccination is demonstrated by the estimated effect on disease burden. During 2010-2020, influenza vaccination was estimated to have averted 1.4 million to 7.5 million illnesses, 0.7 million to 3.5 million medical visits, 39 000 to 105 000 hospitalizations, and 3500 to 12 000 deaths from influenza each season in the US.4

A record number of 194 million to 198 million influenza vaccine doses are expected to be available in the US this influenza season (Figure). Although all persons 6 months or older are recommended by the CDC for influenza vaccination by the end of October, persons remaining unvaccinated are strongly encouraged to continue to pursue vaccination in November and December, and as long as influenza viruses are circulating and vaccine is available.5 Although the extent of influenza activity this season is unpredictable, influenza vaccination can reduce the burden of acute respiratory illness and complications attributable to influenza and thereby decrease the effect of influenza on health care systems so that available health care resources can be focused on patients with COVID-19.

Figure.  Cumulative Doses of Influenza Vaccines Distributed by Week and Season, 2016-2017 to 2020-2021
Cumulative Doses of Influenza Vaccines Distributed by Week and Season, 2016-2017 to 2020-2021

From the Centers for Disease Control and Prevention FluFinder distribution tracking program.

Influenza Vaccination of Persons With COVID-19

Influenza vaccination of hospitalized patients at discharge during influenza season can increase influenza vaccination coverage of persons at high risk for influenza complications. However, there are no available data on the safety, immunogenicity, or effectiveness of influenza vaccines in persons with COVID-19 to inform the optimal timing of influenza vaccination, including for those with severe or critical illness who received short-acting anti-inflammatory therapy (eg, dexamethasone) or long-acting immunomodulators. For persons with suspected or laboratory-confirmed COVID-19, clinicians should consider delaying influenza vaccination of patients with mild illness until at least 10 days after illness onset and improvement in symptoms and 24 hours without fever without antipyretic mediation to reduce transmission risk to vaccinators and defer vaccination of those with moderate and more severe illness until the patient is no longer acutely ill.6 If influenza vaccination is delayed, patients should be reminded to return for influenza vaccination after they have recovered from their acute illness. Specific guidance for vaccinations during the COVID-19 pandemic is available on the CDC’s website.6

Influenza Testing and Antiviral Treatment

Because of overlapping signs, symptoms, and complications, influenza virus infection cannot be distinguished by clinical findings alone from SARS-CoV-2 infection or coinfection with both viruses. When influenza viruses and SARS-CoV-2 are cocirculating in a community, testing is needed to determine whether either virus or coinfection is present in patients presenting with acute respiratory illness. In addition to US Food and Drug Administration (FDA)–cleared influenza nucleic acid detection and rapid influenza antigen detection assays, and SARS-CoV-2 nucleic acid and antigen detection assays that have received FDA Emergency Use Authorization, several multiplex assays that detect both SARS-CoV-2 and influenza A and B viruses have received FDA Emergency Use Authorization.7 These multiplex assays vary in the time to results from 15 to 40 minutes to up to 8 hours and are authorized for a variety of clinical settings, including point-of-care clinic use. For hospitalized patients with suspected influenza, use of nucleic acid detection assays for influenza viruses are recommended to guide antiviral treatment decisions. For outpatients, influenza testing can be done if the results will inform clinical management decisions. SARS-CoV-2 testing and treatment for hospitalized patients and outpatients with suspected and laboratory-confirmed COVID-19 should follow existing guidelines, such as those from the National Institutes of Health.8

Four FDA-approved antivirals are recommended for the treatment of individuals with influenza (oseltamivir, zanamivir, peramivir, and baloxavir). Efficacy of early antiviral treatment of influenza (within 2 days of illness onset) in outpatients has been shown in randomized clinical trials, and observational studies have shown clinical benefit when antiviral treatment is administered at the time of admission to hospitalized patients with influenza.9 Starting antiviral treatment as soon as possible is recommended for the following priority groups: persons requiring hospitalization with suspected influenza (without waiting for influenza testing results) and outpatients with suspected or laboratory-confirmed influenza who have progressive disease or complications or who are at high risk for influenza complications.9

Because antiviral treatment of influenza is most effective when initiated soon after symptoms begin, clinicians should encourage persons at high risk for influenza complications to contact them as soon as they experience acute respiratory illness symptoms if there is local influenza activity. Whether evaluated in a clinical setting or through telemedicine consultation, influenza can be clinically diagnosed in outpatients without influenza testing and empirical antiviral treatment can be prescribed; patients should be advised to start treatment as soon as possible. Clinical algorithms for testing and treatment of influenza when SARS-CoV-2 and influenza viruses are cocirculating are available on the CDC's website.10


The clinical and public health effects of influenza in the US for the upcoming winter during the COVID-19 pandemic are difficult to predict and could vary widely by location and by extent of SARS-CoV-2 community mitigation measures. Annual vaccination remains the best tool for preventing influenza, and vaccine availability is projected at record levels. Initiation of antiviral treatment as soon as possible is recommended for persons with suspected or confirmed influenza who are hospitalized, have progressive disease, or are at high risk for complications. Clinicians should monitor local influenza and SARS-CoV-2 activity (eg, local and state public health surveillance data, testing performed for influenza and COVID-19 at health care facilities) to inform evaluation and treatment of patients with acute respiratory illness.

Back to top
Article Information

Corresponding Author: Timothy M. Uyeki, MD, MPH, MPP, Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H24-7, Atlanta, GA 30329 (tmu0@cdc.gov).

Published Online: November 2, 2020. doi:10.1001/jama.2020.21849

Conflict of Interest Disclosures: None reported.

Disclaimer: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Olsen  SJ, Azziz-Baumgartner  E, Budd  AP,  et al.  Decreased influenza activity during the COVID-19 pandemic.   MMWR Morb Mortal Wkly Rep. 2020;69(37):1305-1309.PubMedGoogle ScholarCrossref
Influenza update. World Health Organization. Published October 26, 2020. Accessed October 28, 2020. https://www.who.int/influenza/surveillance_monitoring/updates/2020_10_26_surveillance_update_379.pdf?ua=1
Disease burden of influenza. Centers for Disease Control and Prevention. Updated October 5, 2020. Accessed October 26, 2020. https://www.cdc.gov/flu/about/burden/index.html
Past seasons estimated influenza disease burden averted by vaccination. Centers for Disease Control and Prevention. Updated October 1, 2020. Accessed October 26, 2020. https://www.cdc.gov/flu/vaccines-work/past-burden-averted-est.html
Grohskopf  LA, Alyanak  E, Broder  KR,  et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices: United States, 2020-21 influenza season.   MMWR Recomm Rep. 2020;69(8):1-24. doi:10.15585/mmwr.rr6908a1PubMedGoogle ScholarCrossref
Interim guidance for routine and influenza immunization services during the COVID-19 pandemic. Centers for Disease Control and Prevention. Updated October 20, 2020. Accessed October 26, 2020. https://www.cdc.gov/vaccines/pandemic-guidance/index.html
Multiplex assays authorized for simultaneous detection of influenza viruses and SARS-CoV-2 by FDA. Centers for Disease Control and Prevention. Updated October 20, 2020. Accessed October 26, 2020. https://www.cdc.gov/flu/professionals/diagnosis/table-flu-covid19-detection.html
Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Updated October 22, 2020. Accessed October 26, 2020. https://www.covid19treatmentguidelines.nih.gov/
Influenza antiviral medications: summary for clinicians. Centers for Disease Control and Prevention. Updated August 31, 2020. Accessed October 26, 2020. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
Information for clinicians on influenza virus testing. Centers for Disease Control and Prevention. Updated October 20, 2020. Accessed October 26, 2020. https://www.cdc.gov/flu/professionals/diagnosis/index.htm
1 Comment for this article
Influenza Vaccination in Japan in the COVID-19 Era
Takuma Hayashi, MBBS, D.M.Sci., GMRC, PhD | National Hospital Organization Kyoto Medical Center
Influenza vaccination reduces the number of people infected with influenza virus by about 50% compared to the number of people infected with influenza virus without vaccination. In addition, influenza vaccination is believed to reduce the number of infected people who die due to influenza infections by about 80% compared to the number of non-vaccinated deaths.

The estimated amount of influenza vaccine to be supplied in the 2020/2021 season is about 31.78 million (equivalent to 63.56 million doses for adults), an increase of about 7% of the 2019 distribution.

According to a report by the Japanese Ministry of Health,
Labor and Welfare, the annual influenza vaccination rate last season was about 50-60% for children and about 40-70% for the elderly. In the 2020/2021 season, the amount of influenza vaccine is expected to increase due to concerns about the epidemic of the new coronavirus infection.

The following populations are to be prioritized for influenza vaccination:

(1) Among those who are subject to regular vaccination based on the Immunization Law, elderly people aged 65 and over, etc.

(2) Medical professionals, those under 65 years old with underlying illness, pregnant women, infants to lower grades of elementary school (second grade of elementary school)

On December 4, 2020, the Japan Ministry of Health, Labor and Welfare announced the latest domestic outbreak of influenza (period November 23-29). In 2019, 27,393 cases of influenza virus infection during the  were reported nationwide. During the same period in 2020, 46 cases were reported. The number of people infected with influenza virus in 2020 (November 23-29) is 1/600 of the number of people infected in the same period in 2019.